Skip to main content

myeloma

Research in Review
06/01/2016
JCP Editors
Carfilzomib, in combination with lenalidomide and dexamethasone (KRd), may be a cost-effective treatment option for patients with relapsed or refractory multiple myeloma, according to the Kyprolis Global Economic...
Carfilzomib, in combination with lenalidomide and dexamethasone (KRd), may be a cost-effective treatment option for patients with relapsed or refractory multiple myeloma, according to the Kyprolis Global Economic...
...
06/01/2016
Journal of Clinical Pathways